JMCC Group has launched a new division, JMCC Scientific, which will research, develop, test and manufacture innovative cannabis-based treatments for a range of medical conditions.
“JMCC Scientific is the natural next step in the evolution of our company,” said JMCC Group Chair & CEO Diane Scott. “For the first three years, we were focused on serving patients by becoming the leading provider of premium-quality Jamaican medical cannabis to the world. Now, with our Scientific division, we are not only growing pharmacopeia-standard medical cannabis, we’re developing best-in-class cannabisbased medical products. We’re also delivering a comprehensive support ecosystem that enables doctors, other medical professionals and patients themselves to collaborate to devise the most effective personalized treatment program.”
Diane Scott, Group Chair and CEO of JMCC
“It’s really our customers who are taking us here. Both medical professionals and patients want safer methods for using cannabis as medicine, including more precise dosing and products specifically developed for the conditions they’re dealing with. Those needs are what we’re responding to with the launch of JMCC Scientific.”
The Canadian-headquartered company’s initial product line encompasses a range of targeted formulations for chronic pain, epilepsy and anxiety with other formulations in development to treat spasticity and other symptoms of Multiple Sclerosis. All JMCC Scientific products are formulated as water-based nano-emulsion formulations in convenient oral sprays, deemed the safest and most effective delivery format, and developed under the guidance of top medical experts from around the world.
JMCC Scientific’s R&D is guided by globally recognized medical specialists, including the company’s Chief Medical Advisor, Dr. Evan Lewis of the renowned Neurology Centre of Toronto for epilepsy, and Dr. Elyad Davidson, Director of the Pain Relief Clinic at Hadassah Hebrew University Medical Center in Israel.
JMCC Scientific is also developing a comprehensive Treatment Support Centre to provide medical cannabis information, education and ongoing support to patients and doctors and other medical professionals, including current research, therapeutic options, prescribing rules and guidance, dosing, potential side effects and contraindications. It will enable doctors to take a personalized approach to prescribing and monitoring to ensure patients are getting the right formulation and dosage as well as tracking results. The Centre will include mobile apps, a dedicated website and access to supplementary patient screening and monitoring aids.
The formation of JMCC Scientific will also support the company’s participation in Project Twenty21, one of the world’s largest medical cannabis research projects, organized and led by United Kingdom-based Drug Science.
For more information:
JMCC
Shelley Boyes
Global Marketing & Communications Director
T: +1 416.272.8981
E: shelley.boyes@jamaicanmedicann.com
Andrea Chrysanthou
Global Public Affairs
T: +1 416.797-8194
E: achrysanthou@globalpublic.com